{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:13:55Z","timestamp":1772892835479,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00415-020-10190-1","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T09:47:38Z","timestamp":1599731258000},"page":"181-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel pathogenic CACNA1A variant causing episodic ataxia type 2 (EA2) spectrum phenotype in four family members and a novel combined therapy"],"prefix":"10.1007","volume":"267","author":[{"given":"Josef","family":"Penkava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chahrokh-Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Munzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"zu","family":"Eulenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Becker-Bense","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"issue":"4","key":"10190_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mdc3.12075","volume":"1","author":"S Kipfer","year":"2014","unstructured":"Kipfer S, Strupp M (2014) The clinical spectrum of autosomal-dominant episodic ataxias. Mov Disord Clin Pract 1(4):285\u2013290. https:\/\/doi.org\/10.1002\/mdc3.12075","journal-title":"Mov Disord Clin Pract"},{"key":"10190_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/b978-0-444-64189-2.00013-5","volume":"155","author":"JC Jen","year":"2018","unstructured":"Jen JC, Wan J (2018) Episodic ataxias. Handb Clin Neurol 155:205\u2013215. https:\/\/doi.org\/10.1016\/b978-0-444-64189-2.00013-5","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"10190_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1212\/01.wnl.0000176069.64200.28","volume":"65","author":"P Imbrici","year":"2005","unstructured":"Imbrici P, Eunson LH, Graves TD, Bhatia KP, Wadia NH, Kullmann DM, Hanna MG (2005) Late-onset episodic ataxia type 2 due to an in-frame insertion in CACNA1A. Neurology 65(6):944\u2013946. https:\/\/doi.org\/10.1212\/01.wnl.0000176069.64200.28","journal-title":"Neurology"},{"issue":"1","key":"10190_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000101675.61074.50","volume":"62","author":"J Jen","year":"2004","unstructured":"Jen J, Kim GW, Baloh RW (2004) Clinical spectrum of episodic ataxia type 2. Neurology 62(1):17\u201322. https:\/\/doi.org\/10.1212\/01.wnl.0000101675.61074.50","journal-title":"Neurology"},{"issue":"5","key":"10190_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.neurol.2010.10.016","volume":"167","author":"F Riant","year":"2011","unstructured":"Riant F, Vahedi K, Tournier-Lasserve E (2011) Hereditary episodic ataxia. Rev Neurol (Paris) 167(5):401\u2013407. https:\/\/doi.org\/10.1016\/j.neurol.2010.10.016","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"10190_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s0092-8674(00)81373-2","volume":"87","author":"RA Ophoff","year":"1996","unstructured":"Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87(3):543\u2013552. https:\/\/doi.org\/10.1016\/s0092-8674(00)81373-2","journal-title":"Cell"},{"issue":"Pt 10","key":"10190_CR7","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/brain\/awm126","volume":"130","author":"JC Jen","year":"2007","unstructured":"Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW (2007) Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 130(Pt 10):2484\u20132493. https:\/\/doi.org\/10.1093\/brain\/awm126","journal-title":"Brain"},{"key":"10190_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/2050313x17706044","author":"DA Isaacs","year":"2017","unstructured":"Isaacs DA, Bradshaw MJ, Brown K, Hedera P (2017) Case report of novel CACNA1A gene mutation causing episodic ataxia type 2. SAGE Open Med Case Rep. https:\/\/doi.org\/10.1177\/2050313x17706044","journal-title":"SAGE Open Med Case Rep"},{"issue":"5","key":"10190_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"10190_CR10","unstructured":"Ellard S, Baple E, Berry I, Forrester N, Turnbull C, Owens M, Eccles D, Abbs S, Scott R, McMullan Z (2019) ACGS Best Practice Guidelines for Variant Classification 2019. Association for Clinical Genomic Science. https:\/\/www.acgs.uk.com\/quality\/best-practice-guidelines\/"},{"issue":"1\u20132","key":"10190_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jns.2010.01.010","volume":"291","author":"E Mantuano","year":"2010","unstructured":"Mantuano E, Romano S, Veneziano L, Gellera C, Castellotti B, Caimi S, Testa D, Estienne M, Zorzi G, Bugiani M, Rajabally YA, Barcina MJ, Servidei S, Panico A, Frontali M, Mariotti C (2010) Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. J Neurol Sci 291(1\u20132):30\u201336. https:\/\/doi.org\/10.1016\/j.jns.2010.01.010","journal-title":"J Neurol Sci"},{"issue":"2","key":"10190_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mgg3.196","volume":"4","author":"N Maksemous","year":"2016","unstructured":"Maksemous N, Roy B, Smith RA, Griffiths LR (2016) Next-generation sequencing identifies novel CACNA1A gene mutations in episodic ataxia type 2. Mol Genet Genomic Med 4(2):211\u2013222. https:\/\/doi.org\/10.1002\/mgg3.196","journal-title":"Mol Genet Genomic Med"},{"issue":"8","key":"10190_CR13","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/ajmg.a.37678","volume":"170","author":"K Reinson","year":"2016","unstructured":"Reinson K, Oiglane-Shlik E, Talvik I, Vaher U, Ounapuu A, Ennok M, Teek R, Pajusalu S, Murumets U, Tomberg T, Puusepp S, Piirsoo A, Reimand T, Ounap K (2016) Biallelic CACNA1A mutations cause early onset epileptic encephalopathy with progressive cerebral, cerebellar, and optic nerve atrophy. Am J Med Genet A 170(8):2173\u20132176. https:\/\/doi.org\/10.1002\/ajmg.a.37678","journal-title":"Am J Med Genet A"},{"issue":"6","key":"10190_CR14","doi-asserted-by":"publisher","first-page":"103530","DOI":"10.1016\/j.ejmg.2018.08.011","volume":"62","author":"C Angelini","year":"2019","unstructured":"Angelini C, Van Gils J, Bigourdan A, Jouk PS, Lacombe D, Menegon P, Moutton S, Riant F, Sole G, Tournier-Lasserve E, Trimouille A, Vincent M, Goizet C (2019) Major intra-familial phenotypic heterogeneity and incomplete penetrance due to a CACNA1A pathogenic variant. Eur J Med Genet 62(6):103530. https:\/\/doi.org\/10.1016\/j.ejmg.2018.08.011","journal-title":"Eur J Med Genet"},{"issue":"2","key":"10190_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"W Ilg","year":"2014","unstructured":"Ilg W, Bastian AJ, Boesch S, Burciu RG, Celnik P, Claassen J, Feil K, Kalla R, Miyai I, Nachbauer W, Schols L, Strupp M, Synofzik M, Teufel J, Timmann D (2014) Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13(2):248\u2013268. https:\/\/doi.org\/10.1007\/s12311-013-0531-6","journal-title":"Cerebellum"},{"key":"10190_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09717-3","author":"J Gandini","year":"2020","unstructured":"Gandini J, Manto M (2020) The neurological update: therapies for cerebellar ataxias in 2020. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-09717-3","journal-title":"J Neurol"},{"issue":"9","key":"10190_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/01.wnl.0000125691.74109.53","volume":"62","author":"M Strupp","year":"2004","unstructured":"Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62(9):1623\u20131625. https:\/\/doi.org\/10.1212\/01.wnl.0000125691.74109.53","journal-title":"Neurology"},{"issue":"3","key":"10190_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","volume":"77","author":"M Strupp","year":"2011","unstructured":"Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77(3):269\u2013275. https:\/\/doi.org\/10.1212\/WNL.0b013e318225ab07","journal-title":"Neurology"},{"issue":"12","key":"10190_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1212\/wnl.28.12.1259","volume":"28","author":"RC Griggs","year":"1978","unstructured":"Griggs RC, Moxley RT 3rd, Lafrance RA, McQuillen J (1978) Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 28(12):1259\u20131264. https:\/\/doi.org\/10.1212\/wnl.28.12.1259","journal-title":"Neurology"},{"issue":"1","key":"10190_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1570159x16666180905093535","volume":"17","author":"R Kalla","year":"2019","unstructured":"Kalla R, Strupp M (2019) Aminopyridines and acetyl-dl-leucine: new therapies in cerebellar disorders. Curr Neuropharmacol 17(1):7\u201313. https:\/\/doi.org\/10.2174\/1570159x16666180905093535","journal-title":"Curr Neuropharmacol"},{"issue":"16","key":"10190_CR21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1212\/wnl.0000000000002041","volume":"85","author":"T Bremova","year":"2015","unstructured":"Bremova T, Malinova V, Amraoui Y, Mengel E, Reinke J, Kolnikova M, Strupp M (2015) Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology 85(16):1368\u20131375. https:\/\/doi.org\/10.1212\/wnl.0000000000002041","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10190-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:26:28Z","timestamp":1631233588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":21,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10190"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10190-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker\u2019s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Gr\u00fcnenthal, GSK, Henning Pharma, Interacoustics, MSD, Mylan, Otometrics, Pierre-Fabre, TEVA, UCB. He is a share holder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion. On behalf of all authors, the corresponding author states that there is no conflict of interest for all other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Our patient and her family members gave their informed written consent to participate in the study, which was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}